Company Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Why Investors Should Care
Generates a return on equity of 59.8%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 39.0%.
Net profit has compounded at 22.7% per year over the last five years.
Revenue has grown at a 20.4% CAGR over the past five years.
Trades at a P/E of 11.2, below the sector median of 24.8.
Maintains a net profit margin of 35.3%.
Recent Developments
- Dec 2025 Revenue of $309.06B (+6.4% YoY); net profit $102.43B.
- Trailing 12 Months Year-on-year growth — revenue +2.1%, earnings -20.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.4%, profit CAGR 22.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.43% |
| 1 Year: | 2.10% |
Compounded Profit Growth
| 5 Years: | 22.65% |
| 1 Year: | -20.60% |
Stock Price Performance
| 1 Year: | -6.99% |
| 6 Months: | +19.19% |
| 3 Months: | +11.50% |
| 1 Month: | -3.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.16 · Neutral
P/E of 11.15 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 59.8%.
- Healthy ROCE of 39.0%.
- Excellent profit margin of 35.3%.
- Compounding revenue at 20.4% over 5 years.
- Profit CAGR of 22.7% over 5 years.
- Attractive dividend yield of 4.16%.
CONS
- Trading 25.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVO Novo Nordisk A/S PHARMA | 45.16 | 11.15 | $150.97B | 4.16% | 39.01% | 59.81% | 20.43% | 22.65% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 78.09B | 76.86B | 74.98B | 79.14B | 96.82B |
| Cost of Revenue | - | 12.89B | 12.85B | 17.90B | 15.15B | 13.60B |
| Gross Profit | - | 65.20B | 64.01B | 57.07B | 64.00B | 83.22B |
| Operating Expenses | - | 26.41B | 30.56B | 33.39B | 32.26B | 23.61B |
| Operating Income | - | 38.79B | 33.45B | 23.68B | 31.74B | 59.62B |
| EBITDA | - | 46.05B | 43.60B | 31.44B | 37.30B | 69.21B |
| Interest Expense | 5.09B | 5.18B | 4.96B | - | -4.41B | 3.50B |
| Pretax Income | - | 37.03B | 33.80B | 25.52B | 34.19B | 62.17B |
| Tax Provision | - | 8.00B | 7.30B | 5.51B | 7.29B | 13.62B |
| Net Income | - | 29.03B | 26.50B | 20.01B | 26.89B | 48.56B |
| Diluted EPS | - | 6.53 | 5.96 | 4.50 | 6.04 | 10.91 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 176.95B | 232.26B | 290.40B | 309.06B |
| Cost of Revenue | 28.45B | 35.77B | 44.52B | 58.79B |
| Gross Profit | 148.51B | 196.50B | 245.88B | 250.28B |
| Operating Expenses | 73.70B | 93.92B | 117.54B | 122.62B |
| Operating Income | 74.81B | 102.57B | 128.34B | 127.66B |
| EBITDA | 76.80B | 114.63B | 147.94B | 156.73B |
| Interest Expense | 378.00M | 542.00M | 1.64B | 4.21B |
| Pretax Income | 69.06B | 104.67B | 127.19B | 130.54B |
| Tax Provision | 13.54B | 20.99B | 26.20B | 28.11B |
| Net Income | 55.52B | 83.68B | 100.99B | 102.43B |
| Diluted EPS | 12.22 | 18.62 | 22.63 | 23.03 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 241.26B | 314.49B | 465.63B | 542.90B |
| Current Assets | - | 108.19B | 139.65B | 161.79B | 172.45B |
| Cash & Equivalents | - | 12.65B | 14.39B | 15.65B | 26.46B |
| Inventory | - | 24.39B | 31.81B | 40.85B | 49.62B |
| Receivables | - | 50.56B | 64.77B | 71.95B | 70.86B |
| Total Liabilities | - | 157.77B | 207.93B | 322.14B | 348.86B |
| Current Liabilities | - | 120.94B | 169.66B | 217.61B | 215.66B |
| Long Term Debt | - | 20.77B | 15.98B | 84.25B | 111.70B |
| Total Debt | - | 25.78B | 27.01B | 102.79B | 130.96B |
| Total Equity | - | 83.49B | 106.56B | 143.49B | 194.05B |
| Shares Outstanding | - | 4.56B | 4.51B | 4.46B | 4.46B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 78.89B | 108.91B | 120.97B | 119.10B |
| Investing Cash Flow | - | -24.92B | -43.89B | -128.90B | -79.16B |
| Financing Cash Flow | - | -51.80B | -63.16B | 8.73B | -28.41B |
| Capital Expenditure | - | -14.75B | -38.90B | -51.31B | -90.11B |
| Free Cash Flow | - | 64.13B | 70.01B | 69.66B | 28.99B |
| Net Change in Cash | - | 2.17B | 1.86B | 808.00M | 11.54B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 83.9% | 84.6% | 84.7% | 81.0% |
| Operating Margin % | 42.3% | 44.2% | 44.2% | 41.3% |
| Net Margin % | 31.4% | 36.0% | 34.8% | 33.1% |
| ROE % | 66.5% | 78.5% | 70.4% | 52.8% |
| ROCE % | 62.2% | 70.8% | 51.7% | 39.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dodge & Cox Inc. | 0.60% | 20.40M | $881.97M |
| 2 | LOOMIS SAYLES & CO L P | 0.55% | 18.59M | $804.02M |
| 3 | Franklin Resources, Inc. | 0.38% | 13.04M | $563.90M |
| 4 | Price (T.Rowe) Associates Inc | 0.35% | 11.70M | $506.11M |
| 5 | Morgan Stanley | 0.34% | 11.66M | $504.17M |
| 6 | Bank of America Corporation | 0.33% | 11.18M | $483.28M |
| 7 | Capital International Investors | 0.29% | 9.72M | $420.34M |
| 8 | Folketrygdfondet | 0.28% | 9.52M | $411.75M |
| 9 | Goldman Sachs Group Inc | 0.27% | 9.18M | $396.96M |
| 10 | Fisher Asset Management, LLC | 0.25% | 8.32M | $359.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVO
Why the CEO of Wegovy maker Novo Nordisk isn't yet sold on the peptide craze
Novo Nordisk's new CEO sounds the alarm on peptides.
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other.
Eli Lilly is worth 5.5x Novo Nordisk but earns nowhere near 5.5x more. Here's how the obesity pill war, a 13x vs. 32x valuation gap, and the dividend stack up, and which one I'd buy.
Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations
A pediatric obesity success collided with another cardiovascular retreat, leaving Novo's concentration problem unresolved.
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commissio…
Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts
Novo Nordisk stock has fallen sharply over the past three years, yet valuation checks still lean toward the shares looking cheap rather than stretched. With fresh questions around obesity drug competition, patent risk and a changing leaders…
NVO — Frequently Asked Questions
What is the current share price of Novo Nordisk A/S (NVO)?
As of 2026-09-19 21:16 PDT, Novo Nordisk A/S (NVO) trades at $45.16 on NYSE. Its 52-week range is $34.33 to $60.94.
What is the market capitalisation of NVO?
Novo Nordisk A/S (NVO) has a market capitalisation of $150.97B on NYSE.
What is the P/E ratio of NVO?
NVO trades at a trailing price-to-earnings (P/E) ratio of 11.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.60.
Does NVO pay a dividend?
Novo Nordisk A/S (NVO) currently offers a dividend yield of 4.16%.
What is the return on equity (ROE) of NVO?
NVO has a return on equity (ROE) of 59.81%. Its return on capital employed (ROCE) is 39.01%.
Is NVO a good stock to buy?
This page provides a data-driven analysis of Novo Nordisk A/S (NVO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.